Advertisement

Chemotherapy for the Lungs

  • Corey J. Langer
  • Jared Weiss
Reference work entry

Abstract

The addition of chemotherapy to definitive radiation for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) improves survival. Although the initial data for superior survival with chemotherapy came from studies using induction chemotherapy before definitive radiation, subsequent studies have shown superior outcomes with concurrent therapy. The combination of cisplatin and etoposide remains the standard of care for patients able to tolerate the regimen. In the context of concurrent definitive chemoradiation with full dose chemotherapy, there is no proven benefit to additional chemotherapy given either before or after chemoradiation. However, consolidation with full dose therapy remains standard following low-dose regimens used for patients unable to tolerate cisplatin and etoposide. Perhaps, the most accepted of these regimens is the locally advanced multimodality protocol (LAMP) regimen of weekly carboplatin and paclitaxel, which in Japan proved equivalent to a cisplatin-containing regimen in combination with radiation. The combination of full dose carboplatin and pemetrexed is also of increasing interest for patients with non-squamous histology. No targeted agent is currently indicated in combination with radiation.

Keywords

Small Cell Lung Cancer Induction Chemotherapy Epidermal Growth Factor Receptor Mutation Prophylactic Cranial Irradiation Tracheoesophageal Fistula 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dillman RO, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88(17):1210–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Sause W, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117(2):58–64.CrossRefGoogle Scholar
  3. 3.
    Furuse K, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Curran W, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Russell A, Byhardt R, Machtay M, Sause W, Cox JD. Phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410. In Press at JNCI, 2010.Google Scholar
  5. 5.
    Fournel P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95–01 Study. J Clin Oncol. 2005;23(25):5910–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Auperin A, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Choy H, WJ, CJ, Scott CB, Bonomi P, Travis P, Haluschak J, Belani CP. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol. 2002; 21 (abstr 1160).Google Scholar
  8. 8.
    Vokes EE, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and leukemia group B. J Clin Oncol. 2007;25(13):1698–704.CrossRefPubMedGoogle Scholar
  9. 9.
    Movsas B, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98–01. J Clin Oncol. 2005;23(10):2145–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Lawrence YR, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Wasserman T, Byhardt R, Movsas B. Carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: a long-term follow-up of Radiation Therapy Oncology Group (RTOG) 98–01. 2010: Personal communication from Corey Langer to Jared Weiss, 11/4/2010.Google Scholar
  11. 11.
    Satouchi NY, Chiba Y, Kudoh S, Hida T, Kubo A, Seto T, Nishimura Y, Nakagawa K, Fukuoka M. Randomized, phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (NSCLC): WJTOG0105. J Clin Oncol 27:15s, 2009 (suppl; abstr 7504).Google Scholar
  12. 12.
    Schaake-Koning C, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326(8):524–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Kiura NT, Segawa Y, Kamei H, Takemoto M, Tabata M, Ueoka H, Hiraki S, Matsuo K, Tanimoto M. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7515).Google Scholar
  14. 14.
    Segawa Y, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol.Google Scholar
  15. 15.
    Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Govindan R, Wang X, Hodgson L, Kratzke R, Vokes EE. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 27:15s, 2009 (suppl; abstr 7505).Google Scholar
  17. 17.
    Vokes EE, et al. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009;10(3):193–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Bonner JA, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Pirker R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Blumenschein GR, Curran WJ, Robert F, Fossella FV, Werner-Wasik M, Doescher P, Choy H, Komaki R. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7516).Google Scholar
  21. 21.
    Govindan JB, Wang X, Hodgson L, Kratzke R, Vokes EE. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. Clin Oncol. 27:15s, 2009 (suppl; abstr 7505).Google Scholar
  22. 22.
    Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Spigel DR, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28(1):43–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Stinchcombe TE, et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009;4(9):1117–25.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gandara DR, Gaspar LE, Albain KS, Lara PN, Crowley J. Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7059.Google Scholar
  26. 26.
    Hanna N, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008;26(35):5755–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Green MR, et al. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. J Thorac Oncol. 2009;4(8):983–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim ES, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–18.CrossRefPubMedGoogle Scholar
  29. 29.
    Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMedGoogle Scholar
  30. 30.
    Cappuzzo F, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Kelly K, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990;61(4):584–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pignon JP, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Auperin A, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84.CrossRefPubMedGoogle Scholar
  36. 36.
    Murray N, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11(2):336–44.CrossRefPubMedGoogle Scholar
  37. 37.
    Takada M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054–60.CrossRefPubMedGoogle Scholar
  38. 38.
    Turrisi 3rd AT, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.CrossRefPubMedGoogle Scholar
  39. 39.
    Ettinger DS, et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol. 2005;23(22):4991–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Giaccone G, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23(28):6854–64.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Medicine, Division of Hematology-OncologyHospital of the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Medicine, Division of Hematology-OncologyUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations